John Virostko1, Garrett Kuketz2, Erin Higgins2, Chengyue Wu2, Anna G Sorace3, Julie C DiCarlo4, Sarah Avery5, Debra Patt6, Boone Goodgame7, Thomas E Yankeelov8. 1. Department of Diagnostic Medicine, University of Texas at Austin, Austin, TX, USA; Livestrong Cancer Institutes, University of Texas at Austin, Austin, TX, USA; Department of Oncology, University of Texas at Austin, Austin, TX, USA. Electronic address: jack.virostko@austin.utexas.edu. 2. Department of Biomedical Engineering, University of Texas at Austin, Austin, TX, USA. 3. Department of Biomedical Engineering, University of Alabama at Birmingham, Birmingham, AL, USA; O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA. 4. Institute for Computational Engineering and Sciences, University of Texas at Austin, Austin, TX, USA. 5. Austin Radiological Association, Austin, TX, USA. 6. Texas Oncology, Austin, TX, USA. 7. Seton Hospital, Austin, TX, USA; Department of Internal Medicine, University of Texas at Austin, Austin, TX, USA. 8. Department of Diagnostic Medicine, University of Texas at Austin, Austin, TX, USA; Livestrong Cancer Institutes, University of Texas at Austin, Austin, TX, USA; Department of Oncology, University of Texas at Austin, Austin, TX, USA; Department of Biomedical Engineering, University of Texas at Austin, Austin, TX, USA; Institute for Computational Engineering and Sciences, University of Texas at Austin, Austin, TX, USA; Department of Imaging Physics, MD Anderson Cancer Center, Houston, TX, USA.
Abstract
PURPOSE: This study assesses the rate of enhancement of breast fibroglandular tissue after administration of a magnetic resonance imaging (MRI) gadolinium-based contrast agent and determines its relationship with response to neoadjuvant therapy (NAT) in women with breast cancer. METHOD: Women with locally advanced breast cancer (N = 19) were imaged four times over the course of NAT. Dynamic contrast-enhanced (DCE) MRI was acquired after administration of a gadolinium-based contrast agent with a temporal resolution of 7.27 s. The tumor, fibroglandular tissue, and adipose tissue were semi-automatically segmented using a manually drawn region of interest encompassing the tumor followed by fuzzy c-means clustering. The rate and relative intensity of signal enhancement were calculated for each voxel within the tumor and fibroglandular tissue. RESULTS: The rate of fibroglandular tissue enhancement after contrast agent injection declined by an average of 29 % over the course of NAT. This decline was present in 16 of the 19 patients in the study. The rate of enhancement is significantly higher in women who achieve pathological complete response (pCR) after both 1 cycle (68 % higher, p < 0.05) and after 3-5 cycles of NAT (58 % higher; p < 0.05). The relative intensity of fibroglandular enhancement correlates with the rate of enhancement (R2 = 0.64, p < 0.001) and is higher in women who achieve pCR after both 1 cycle and after 3-5 cycles of NAT (p < 0.05, both timepoints). CONCLUSION: The rate of fibroglandular tissue enhancement declines over the course of therapy, provides novel information not reflected by tumoral measures, and may predict pathological response early in the course of therapy, with smaller declines in enhancement in women who achieve favorable response.
PURPOSE: This study assesses the rate of enhancement of breast fibroglandular tissue after administration of a magnetic resonance imaging (MRI) gadolinium-based contrast agent and determines its relationship with response to neoadjuvant therapy (NAT) in women with breast cancer. METHOD: Women with locally advanced breast cancer (N = 19) were imaged four times over the course of NAT. Dynamic contrast-enhanced (DCE) MRI was acquired after administration of a gadolinium-based contrast agent with a temporal resolution of 7.27 s. The tumor, fibroglandular tissue, and adipose tissue were semi-automatically segmented using a manually drawn region of interest encompassing the tumor followed by fuzzy c-means clustering. The rate and relative intensity of signal enhancement were calculated for each voxel within the tumor and fibroglandular tissue. RESULTS: The rate of fibroglandular tissue enhancement after contrast agent injection declined by an average of 29 % over the course of NAT. This decline was present in 16 of the 19 patients in the study. The rate of enhancement is significantly higher in women who achieve pathological complete response (pCR) after both 1 cycle (68 % higher, p < 0.05) and after 3-5 cycles of NAT (58 % higher; p < 0.05). The relative intensity of fibroglandular enhancement correlates with the rate of enhancement (R2 = 0.64, p < 0.001) and is higher in women who achieve pCR after both 1 cycle and after 3-5 cycles of NAT (p < 0.05, both timepoints). CONCLUSION: The rate of fibroglandular tissue enhancement declines over the course of therapy, provides novel information not reflected by tumoral measures, and may predict pathological response early in the course of therapy, with smaller declines in enhancement in women who achieve favorable response.
Authors: Laura J Esserman; Donald A Berry; Angela DeMichele; Lisa Carey; Sarah E Davis; Meredith Buxton; Cliff Hudis; Joe W Gray; Charles Perou; Christina Yau; Chad Livasy; Helen Krontiras; Leslie Montgomery; Debasish Tripathy; Constance Lehman; Minetta C Liu; Olufunmilayo I Olopade; Hope S Rugo; John T Carpenter; Lynn Dressler; David Chhieng; Baljit Singh; Carolyn Mies; Joseph Rabban; Yunn-Yi Chen; Dilip Giri; Laura van 't Veer; Nola Hylton Journal: J Clin Oncol Date: 2012-05-29 Impact factor: 44.544
Authors: Nola M Hylton; Jeffrey D Blume; Wanda K Bernreuter; Etta D Pisano; Mark A Rosen; Elizabeth A Morris; Paul T Weatherall; Constance D Lehman; Gillian M Newstead; Sandra Polin; Helga S Marques; Laura J Esserman; Mitchell D Schnall Journal: Radiology Date: 2012-06 Impact factor: 11.105
Authors: Talal Hilal; Matthew Covington; Heidi E Kosiorek; Christine Zwart; Idris T Ocal; Barbara A Pockaj; Donald W Northfelt; Bhavika K Patel Journal: Breast J Date: 2018-07-31 Impact factor: 2.431
Authors: Nima Nabavizadeh; Catherine Klifa; David Newitt; Ying Lu; Yunn-Yi Chen; Howard Hsu; Clark Fisher; Taku Tokayasu; Adam B Olshen; Paul Spellman; Joe W Gray; Nola Hylton; Catherine C Park Journal: Integr Biol (Camb) Date: 2011-03-18 Impact factor: 2.192
Authors: Geraldine J Liao; Leah C Henze Bancroft; Roberta M Strigel; Rhea D Chitalia; Despina Kontos; Linda Moy; Savannah C Partridge; Habib Rahbar Journal: J Magn Reson Imaging Date: 2019-04-19 Impact factor: 4.813
Authors: Jona Hattangadi; Catherine Park; James Rembert; Catherine Klifa; Jimmy Hwang; Jessica Gibbs; Nola Hylton Journal: AJR Am J Roentgenol Date: 2008-06 Impact factor: 3.959
Authors: Adam Olshen; Denise Wolf; Ella F Jones; David Newitt; Laura J van ‘t Veer; Christina Yau; Laura Esserman; Julia D Wulfkuhle; Rosa I Gallagher; Lisa Singer; Emanuel F Petricoin; Nola Hylton; Catherine C Park Journal: J Med Imaging (Bellingham) Date: 2017-12-23
Authors: Nathaniel M Braman; Maryam Etesami; Prateek Prasanna; Christina Dubchuk; Hannah Gilmore; Pallavi Tiwari; Donna Plecha; Anant Madabhushi Journal: Breast Cancer Res Date: 2017-05-18 Impact factor: 6.466
Authors: Angela M Jarrett; Anum S Kazerouni; Chengyue Wu; John Virostko; Anna G Sorace; Julie C DiCarlo; David A Hormuth; David A Ekrut; Debra Patt; Boone Goodgame; Sarah Avery; Thomas E Yankeelov Journal: Nat Protoc Date: 2021-09-22 Impact factor: 13.491